Werle E, Bostedt A, Fiehn W, Hasslacher C
Medizinischen Klinik und Poliklinik, Universitätsklinik Heidelberg, Bundesrepublik Deutschland.
Wien Klin Wochenschr Suppl. 1991;189:59-62.
The clinical aspects of the excretion of beta-N-acetylglucosaminidase (beta-NAG, EC 3.2.1.30) in urine of type I and type II diabetics with and without nephropathy are evaluated. Correlation between concentration of albumin and of beta-NAG activity in urine is determined and the circadian rhythm of beta-NAG excretion in urine is examined, the indication of glomerular and tubulointerstitial damage is discussed. Longitudinal studies should demonstrate, whether an increased beta-NAG activity in urine of diabetics with normoalbuminuria is an indicator of nephropathy or a predictor of nephropathy if raised albuminuria is observed.
评估了伴有和不伴有肾病的Ⅰ型和Ⅱ型糖尿病患者尿液中β-N-乙酰氨基葡萄糖苷酶（β-NAG，EC 3.2.1.30）排泄的临床情况。确定了尿中白蛋白浓度与β-NAG活性之间的相关性，检查了尿中β-NAG排泄的昼夜节律，并讨论了肾小球和肾小管间质损伤的指征。纵向研究应证明，正常白蛋白尿的糖尿病患者尿中β-NAG活性增加是否是肾病的指标，或者在出现蛋白尿增加时是否是肾病的预测指标。
